Interpretation of antiretroviral testing is complicated by many factors, including those related to HIV biology and genetics, as well as the intricacies of drug selection pressure in vivo. These complex factors can limit the usefulness of resistance testing. However, knowledge about these issues can help to avoid misinterpreting resistance test results and thereby help clinicians to use resistance testing to individualize antiretroviral drug choices.
References
1.
KempS.D., ShiC., BloorS., HarriganP.R., JW.M., & LarderB.A.1998. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2’,3′-dideoxy-3′-thiacytidine. Journal of Virology1998; 72: 5093–5098.
2.
NijhuisM., SchuurmanR., de JongD., van LeeuwenR., LangeJ., DanneS., KeulenW., de GrootT., & BoucherC.A.Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo.Journal of Infectious Diseases, 1997; 176: 398–405.
3.
WhitcombJ.M., LimoliK., WrinT., SmithD., TianH., ParkinN., LieY.S., & PetropoulosC.J.Phenotypic and genotypic analysis of stavudine-resistant isolates of HIV-1. Antiviral Therapy1998; 3 (Suppl. 1): 14–15.
4.
BloorS., HertogsK., DesmerR.L., PauwelsR., & LarderB.A.Virological basis for HIV-1 resistance to stavudine investigated by analysis of clinical samples. Antiviral Therapy1998; 3 (Suppl. 1): 13–14.
5.
WintersM.A., CoolleyK.L., GirardY.A., LeveeD.J., HamdanH., ShaferR.W., KatzensteinD.A., & MeriganT.C.A 6-base-pair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. Journal of Clinical Investigation1998; 102: 1769–75.
6.
ShaferR.W., KozalM.J., WintersM.A., IversenA.K., KatzensteinD.A., RagniM.V., MeyerW.A.R., GuptaP., RasheedS., CoombsR.Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. Journal of Infectious Diseases1994; 169: 722–9.
7.
ShirasakaT., KavlickM.F., UenoT., GaoW.Y., KojimaE., AlcaideM.L., ChokekijchaiS., RoyB.M., ArnoldE., YarchoanR., & MitsuyaH.Emergence of HIV-1 variants with resistance to multiple dideoxynuceleosides in patients receiving therapy with dideoxynucelosides. Proceedings of the National Academy of Sciences, USA1995; 92: 2398–2402.
8.
Martinez-PicadoJ., SuttonL., DePasqualeM. P., SavaraA.V., & D'AquilaR.T.Human immunodeficiency virus type 1 cloning vectors for antiretroviral resistance testing. Journal of Clinical Microbiology1999; 37: 2943–2951.
9.
Martinez-PicadoJ., SavaraA., SuttonL., & D'AquilaR.T.Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. Journal of Virology1999; 73: 3744–3752.
10.
DulioustA., PaulousS., GuillemotL., DelavalleA.M., BoueF., & ClavelF.Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors. Journal of Virology1999; 73: 850–4.
11.
FayeA., RaceE., ObryV., PrevotM.H., JolyV., MatheronS., DamondF., DamE., PaulousS., & ClavelF.Viral fitness in patients with discordant CD4 and plasma HIV RNA evolution following protease inhibitor failure.6th Conference on Retroviruses and Opportunistic Infections. Chicago, Ill., 1999; Abstract 331.
12.
StoddartC., MammanoF., MorenoM., Linquist-SteppsV., BareC., ClavelF.Lack of fitness of protease inhibitor resistant HIV-1 in vivo.6th Conference on Retroviruses and Opportunistic Infections. Chicago, Ill., 1999; Abstract 4.
13.
D'AquilaR.T., JohnsonV.A., WellesS.L., JapourA.J., KuritzkesD.R., DeGruttolaV., ReichelderferP.S., CoombsR.W., CrumpackerC.S., KahnJ.O., RichmanD.R. for AIDS Clinical Trials Group Protocol 116B / 117 Team and the Virology Committee Resistance Working Group. Zidovudine resistance and human immunodeficiency virus type 1 disease progression during antiretroviral therapy. Annals of Internal Medicine1995; 122: 401–408.
GarraffoR., DurantJ., ClevenberghP., IcardS., ShapiroJ.M., & DellamonicaP.Relevance of protease inhibitor plasma levels in patients treated with genotype adapted therapy: pharmacological data from the Viradapt study. Antiviral Therapy1999; 4 (Suppl. 1): 75–76.
16.
KempfD., MoH., BrunS., MollaA., BernsteinB., HertogsK., LarderB., OrthK., FieldsC., KingM., XuY., JapourA., & SunE.Analysis of virological response to ABT-378/ritonavir therapy in protease inhibitor-experienced patients with respect to baseline viral phenotype and genotype. Antiviral Therapy1999; 4 (Suppl. 1): 6–7.
17.
DeGruttolaV., DixL., D'AquilaR., HolderD., PhillipsA., Ait-KhaledM., BaxterJ., ClevenberghP., HammerS., HarriganR., KatzensteinD., LanierR., MillerM., ParaM., YerlyS., ZolopaA., MurrayJ., PatickA., MillerV., CastilloS., PedneaultL., & MellorJ.The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Therapy2000; 5: 41–48.
18.
HavlirD.V., PetropoulosC.J., HellmannN.S., WhitcombJ.M., & RichmanD.D., for the ACTG 343 Team. Evolution of drug resistance associated with loss of viral suppression in patients treated with indinavir, lamivudine, and zidovudine. Abstract, Journal of the American Medical Association2000 (in press).
19.
DePasqualeM.P., MurphyR., KuritzkesD., Martinez-PicadoJ., SommadossiJ-P, GulickR., SmeatonL., DeGruttolaV., CaliendoA., SuttonL., SavaraA., & D'AquilaR.T.Resistance during early virologic rebound on amprenavir + zidovudine + lamivudine triple therapy or amprenavir monotherapy in ACTG protocol 347. Antiviral Therapy1998; 3 (Suppl. 1): 50–51.
20.
DescampsD., CalvezV., FlandreP., PialouxG., RaffiF., DelaguerreC., CollinG., MeifreddyV., PeytavinG., AboulkerJ.P., & Brun-VezinetF., ANRS 072 Trilege Group. Genotypic resistance analyses of plasma HIV-1 RNA in patients failing to the maintenance phase in Trilege trial. AIDS1998; 12 (Suppl. 4): S11.
21.
DePasqualeM.P., KartsonisN., Martinez-PicadoJ., EronJ., FiscusS., SchockJ., SmeatonL., GulickR., MurphyR., & D'AquilaR., for the ACTG 347/850 team. Selection of protease resistance mutations in semen.6th Conference on Retroviruses and Opportunistic Infections. Chicago, Ill., 1999; Abstract Late Breaker 11.
22.
WongJ.K., IgnacioC.C., TorrianiF., HavlirD., FitchN.J., & RichmanD.D.In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. Journal of Virology1997; 71: 2059–2071.
23.
LeeC.G., GottesmanM.M., CardarelliC.O., RamachandraM., JeangK.T., AmbudkarS.V., PastanI., & DeyS.HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry; 17: 3594–3601.
24.
KimA.E., DintamanJ.M., WaddellD.S., & SilvermanJ.A.Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. Journal of Pharmacology and Experimental Therapeutics; 286: 1439–1445.
25.
KimR.B., FrommM.F., WandelC., LeakeB., WoodA.J., RodenD.M., & WilkinsonG.R.The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. Journal of Clinical Investigation; 15: 289–294.
26.
SchuetzJ.D., ConnellyM.C., SunD., PaibirS.G., FlynnP.M., SrinivasR.V., KumarA., & FridlandA.MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nature Medicine; 5: 1048–1051.
27.
HirschM.S., ConwayB., D'AquilaR.T., JohnsonV.A., Brun-VezinetF., ClotetB., DemeterL.M., HammerS.M., JacobsenD.M., KuritzkesD.R., LovedayC., MellorsJ. W., VellaS., & RichmanD.D.Antiretroviral drug resistance testing in HIV Infection of adults: Implications for clinical management. Journal of the American Medical Association279: 1984–1991.
